The HIV community eagerly awaits data from the PURPOSE 1 clinical trial of lenacapavir for preexposure prophylaxis, which showed a 100% effectiveness in preventing infection. The trial enrolled over 5000 young girls and women in South Africa and Uganda. The results, presented by Linda-Gail Bekker, will be discussed at the International AIDS Conference in Munich. Specialists are excited about the prospect of long-acting PrEP options like lenacapavir, which only requires twice-yearly dosing. Concerns remain about adherence, side effects, and accessibility of the treatment. The potential of lenacapavir as a new class of drug for HIV may offer an alternative to existing treatments.
Source link
PURPOSE 1 Lenacapavir Results ‘Highly Anticipated’
